In Silico Comparison of Human ACE2 Interactions with SARS-CoV-2 Variants of Concern
Overview
As the current pandemic continues on, it is important to understand how different variants of SARS-CoV-2 (the virus responsible for COVID-19) bind onto a human cell to gain entry. My research tries to find the differences in the way the spike proteins of variants of concern of SARS-CoV-2 intact with the human ACE2 receptor. See the full paper here! https://docs.google.com/document/d/1YI6Su1vWAl0eqvk6hRWfZa27wvtlzZ3btj_Ktr6w9Io/edit?usp=sharing
Video
This video could not be played here. Watch it on the original project page.
Abstract
The coronavirus SARS-CoV-2, responsible for the ongoing COVID-19 pandemic, must enter human cells before being able to replicate. The spike protein on the surface of the virus binds to an Angiotensin Converting Enzyme 2 (ACE2) receptor to gain access to the cells. As SARS-CoV-2 spreads and forms different variants, the interactions between the spike protein and ACE2 receptor change. Understanding the differences among these variants is critical in creating more informed responses to this pandemic. This study analyzed the differences among the binding of spike proteins from the Alpha, Beta, Gamma, and wild-type variants of SARS-CoV-2 and the human ACE2 by modeling their initial binding interactions and comparing the binding affinities, dissociation constants, and the interactions that make up the interfaces. These variants of SARS-CoV-2 are classified by the World Health Organization as variants of concern, meaning they show a significant change in the virus’ epidemiology, show an increase in transmissibility or virulence, or pose a threat to current measures to protect public health. Modeling the initial binding interactions and comparing the binding affinities, dissociation constants, and interactions that make up the interface showed significant differences in these properties. Most notably in this study, it was found that the wild-type SARS-CoV-2, had the highest binding affinity at -15.5 kcal/mol at 25 ℃ compared to the other variants tested, whilst the Alpha variant had the lowest at -12.2 kcal/mol. After binding interactions were modeled for the Alpha, Beta, and Gamma spike proteins of SARS-CoV-2 with ACE2, the interactions that made up the interface were listed and compared to the interactions from the binding of ACE2 and the wild-type SARS-CoV-2 spike protein. After counting the similar and unique interfacial interactions for every variant, it was found that the Alpha variant had the greatest number of unique interfacial interactions when compared with wild-type SARS-CoV-2. In contrast, this study shows that the Beta variant had the most similar interfacial interactions, compared to wild-type, when bound to ACE2.
Read the full presentation here!
https://docs.google.com/document/d/1YI6Su1vWAl0eqvk6hRWfZa27wvtlzZ3btj_Ktr6w9Io/edit
From the student
Hello! I'm Sebastian.
I applied to the New Hampsire Academy of Science when a friend recommended it to me, though I never imagined that it I could be doing this sort of research. Protein modeling was interesting to me because of the current pandemic we are living in, and I wanted to learn more about how this virus works, how it is changing, and what that means for our response.
Again, I want to thank the New Hampshire Academy of Science and my mentors Dr. Alyson Michael and Dr. Peter Faletra for this amazing experience!
Images (17)
Awards (1)
- AJAS Fellows Badge
Competition history
- AJAS 2022
Related projects
AJAS · 2022
Computational Analysis of SARS-CoV-2 Variants’ Binding with Vertebrate ACE2
ISEF · 2022
Predicting Virus-Human Interactions To Facilitate the Design of Anti-Coronavirus Vaccines and Therapeutics
ISEF · 2022
Computational Analysis of SARS-CoV-2 Variants' Binding With Vertebrate ACE2
ISEF · 2022
The Effect of Amino Acid Mutagenesis on the Binding Affinity of SARS-CoV-2 Monoclonal Antibodies
AJAS · 2024
Identifying Possible Biological Processes Affected by Non-Target Proteins of SARS-CoV-2
ISEF · 2021
The Effect of Coronavirus Species on the Binding Strength to a Neutralizing Antibody
ISEF · 2023
A Study of the Complex of Human Protein IRF3 and Viral Protein (SARS-CoV-2) ORF7a
ISEF · 2021
Analyzing the Efficacies of Potential Inhibitors of Drug Targets Human Receptor ACE2 and Viral Replication Enzyme RdRp Against SARS-CoV-2
Closest projects by meaning, across every fair and year in the corpus.